医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Micro Blood Science Inc.: Announcement of Developing the Next Generation Blood Test System Which Integrates the High Accuracy Finger Prick Blood Test Technology into Blockchain

2018年01月30日 PM02:09
このエントリーをはてなブックマークに追加


 

TOKYO

Micro Blood Science Inc. (hereinafter MBS), a Japanese blood testing device firm, today announces its plan to develop the next-generation blood test data management system which will securely store the blood test data derived from its proprietary finger prick blood test system, Lifee, thereby allowing the data to be used in a wide variety of medical and healthcare-related services.

MBS not only aims to create the worldwide healthcare eco system based on its innovative blood test services but also to increase the value of the test data information managed by the service users themselves.

In constructing this blood test results data platform, MBS seeks funding domestically and internationally through ICO. The white paper and the further details of the ICO such as the specifications of the tokens for sale and the timeframe of the transactions will become available on our information website in coming days.

About Micro Blood Science Inc.
Established in June 2006 and based in Tokyo, MBS manufactures microliter-scale blood sampling devices and operates the Lifee personal health record system. It also operates the MBS Laboratory model compact lab, which conducts commercial sample analysis using specialized high-level testing and ICT technology, and functions as the hub of the Lifee service.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180129006288/en/

CONTACT

Micro Blood Science Inc.
Kei Ohtake or Minori Sameshima,
+81-3-6240-9200
mbs_ico@microbs.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品工業によるシャイアーの買収案を日本の公正取引委員会が承認
  • 武田拟收购Shire plc获得日本公平交易委员会批准
  • James Till教授因干细胞发现而荣获2018年度江户川Niche奖
  • Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
  • Brightree发布面向居家医疗器械的首个患者App